Commercialisation director joins Edinburgh BioQuarter

Life sciences entrepreneur Michael Capaldi joins Scotland\'s flagship project

Commercialisation director joins Edinburgh BioQuarter
Michael Capaldi, scientist and life sciences entrepreneur, has been named as director of commercialisation for the Edinburgh BioQuarter – Scotland’s flagship project for the life sciences sector.

Capaldi will lead a team of up to 15 people to progress a £12m commercialisation project that will bridge the gap between industry and research.

Capaldi has more than 26 years’ experience in the pharmaceutical and life sciences industries within the UK, Europe and the US.

You may also like

Research & Development

University of Edinburgh to collaborate with Galapagos on cancer therapies

Two-year partnership with plans to extend
Research & Development
Adragos signs agreement with Towa Pharmaceutical to supply off-patent medicines

Adragos signs agreement with Towa Pharmaceutical to supply off-patent medicines

Adragos Pharma Kawagoe KK has announced the signing of an agreement with Towa Pharmaceutical Co., Ltd, to establish a strategic collaboration aimed at ensuring the stable supply of off-patent pharmaceuticals
Manufacturing
SCHOTT Pharma and SHL Medical enhance home-based large-volume injections for patients

SCHOTT Pharma and SHL Medical enhance home-based large-volume injections for patients

SCHOTT Pharma and SHL Medical have joined forces to introduce the first large-volume cartridge in an autoinjector
Regulatory
Sanofi expands vaccine manufacturing in Abu Dhabi as NICE backs its diabetes therapy

Sanofi expands vaccine manufacturing in Abu Dhabi as NICE backs its diabetes therapy

Sanofi advances on two fronts: a new Abu Dhabi vaccine innovation centre with AI and mRNA capabilities and UK NICE backing for teplizumab, the first disease-modifying treatment for type 1 diabetes
Research & Development
PharmNovo reports broader therapeutic potential for PN6047

PharmNovo reports broader therapeutic potential for PN6047

PharmNovo AB has announced new preclinical findings supporting the potential of PN6047 in migraine and opioid withdrawal syndrome. The findings were generated through the company's NIDA-funded collaboration with researchers at Washington University School of Medicine
Sustainability
Haier Biomedical introduces higher capacity benchtop centrifuge with rapid pre-cooling

Haier Biomedical introduces higher capacity benchtop centrifuge with rapid pre-cooling

Haier Biomedical – a trusted partner in reliable laboratory equipment – has introduced the LX-155T750R, its latest high-speed, benchtop centrifuge featuring ECO fastBlast pre-cooling technology
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development
Neuropsychiatric medicine reaches an inflexion point: regulation, science and the road to commercial reality

Neuropsychiatric medicine reaches an inflexion point: regulation, science and the road to commercial reality

Shaped by accelerating regulatory support, expanding clinical evidence and growing institutional acceptance, psychedelic medicine is entering a pivotal phase, reports Joel Latham, Chief Executive Officer, President and Director at Incannex Healthcare Inc.
Subscribe now